DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tuberculosis vaccines
Tuberculosis vaccines
Development of New Vaccines for Tuberculosis
State of the World's Vaccines and Immunization
(COVID-19), Chemical Structure, Therapeutics, Drugs and Vaccines
TB Vaccine R&D Roadmap Background Document
Tuberculosis Vaccines—A New Kid on the Block
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System As a Potential Vaccine Platform
Applying Customer Development Methodology to Industries Under
What's New in Tuberculosis Vaccines?
R01hosei Coronavirus.Pdf
Immunisation Handbook 2020: 21: Tuberculosis
Diagnostic Biomarkers and Improved Vaccination Against Mycobacterial Infection
Questions and Answers on Tuberculosis Vaccines
Tuberculosis Vaccines PIPELINE REPORT 2019
TIPICO IX: Report of the 9 Interactive Infectious Disease Workshop On
BCG Vaccine Package Insert
Current Affairs (Consolidation)
WHO Report on BCG Vaccine Use for Protection Against Mycobacterial
Full Version
Top View
IDMA Bulletin 21St June 2021
Safety and Efficacy of MVA85A, a New Tuberculosis Vaccine, in Infants Previously Vaccinated with BCG: a Randomised, Placebo-Controlled Phase 2B Trial
Pipeline Report » 2020 Tuberculosis Vaccines PIPELINE REPORT 2020
IDMA Bulletin 7Th June 2021
Perspectives
Tuberculosis Vaccine Candidates Based on Mycobacterial Cell Envelope Components
Update on TB Vaccine Pipeline
Getting from Vaccine Hesitancy to Acceptance
Overview of Planned and Ongoing Clinical Studies of Vaccines for COVID-19
For Whose Benefit? Transparency in the Development and Procurement of COVID-19 Vaccines
An Overview of the Development of New Vaccines for Tuberculosis
Current Advances in the Development of Drug and Vaccine for Tuberculosis Prevention and Treatment
Neonatal and Infant Immunity for Tuberculosis Vaccine Development: Importance of Age-Matched Animal Models Laylaa Ramos1,*, Joan K
Potential Effects of Vaccinations on the Prevention of COVID-19: Rationale, Clinical Evidence, Risks, and Public Health Considerations
WHO Preferred Product Characteristics for New Tuberculosis Vaccines
Co-Immune: a Case Study on Open Innovation for Vaccination Hesitancy and Access Camille M
Safety and Immunogenicity of the Gamtbvac
First Draft; June 28 2021; Please Do Not Circulate Or Cite
Tuberculosis
The-Recitals-June-2021-Vajiram.Pdf
The Case for Assessing the Full Value of New Tuberculosis Vaccines
IHP News 632 : a Grim Week (/Era)
The Lung Mucosa and Its Impact on Mycobacterium Tuberculosis Pathogenesis and Bacillus Calmette-Guérin Vaccine Efficacy
Draft Global Roadmap for Research and Development for Tuberculosis Vaccines
GIVE IT a SHOT! RESOURCE PACK Introduction We Can Catch Infectious Diseases Quite Easily: Some Through the Air and Some by Touch
A Summary of the SARS-Cov-2 Vaccines and Technologies Available Or Under Development
NIH Public Access Author Manuscript Vaccine
Global Roadmap for Research and Development of Tuberculosis Vaccines
Review of Vaccine Price Data Submitted by WHO European Region Member States Through the WHO/UNICEF Joint Reporting Form for 2013
Moving Tuberculosis Vaccines from Theory to Practice
EMBL Programme 2017-2021: Digital Biology
Access to COVID-19 Vaccines: Global Approaches in a Global Crisis